{"_id": "65013a93fddc0bb1312fb03a", "and": [{"$and": [{"age": {"$gt": 70}}, {"consultation with the Medical Monitor": true}]}, {"diagnosis": "metastatic Stage IV NSCLC without EGFR, ALK, or ROS genomic alterations"}, {"$or": [{"additional line of therapy with appropriate targeted therapy for patients with actionable mutations (other than EGFR, ALK, or ROS genomic alterations)": true}, {"$and": [{"documented radiographic disease progression on or after first-line therapy": true}, {"$or": [{"concurrent or sequential ICI and platinum-based chemotherapy \u00b1 bevacizumab": true}, {"no more than 1 prior line if ICI and platinum-based chemotherapy were administered concurrently": true}, {"no more than 2 prior lines for sequential administration of platinum-based chemotherapy and ICI as 2 separate lines": true}]}]}, {"$and": [{"LN-145 manufacture allowed for patients with residual resectable disease after completion of platinum-based chemotherapy component of front-line ICI and platinum-based chemotherapy combination": true}, {"meet all eligibility criteria except documented disease progression": true}, {"intend to receive TIL therapy after disease progression": true}]}, {"$and": [{"prior systemic therapy in adjuvant or neoadjuvant setting, or as part of definitive chemoradiotherapy": true}, {"count as a line of therapy if patient had disease progression during or within 12 months after completion of such therapy": true}]}, {"resectable lesion for TIL production": true}, {"remaining measurable lesion as defined by RECIST v1.1": true}, {"adequate organ function": true}, {"LVEF > 45%, NYHA Class 1": true}, {"adequate pulmonary function": true}, {"ECOG performance status of 0 or 1": true}, {"$and": [{"patients of childbearing potential or those with partners of childbearing potential": true}, {"willing to practice an approved method of highly effective birth control during treatment and up to 12 months after all protocol-related therapy": true}]}]}, {"$not": {"$or": [{"EGFR driver mutation": true}, {"ALK driver mutation": true}, {"ROS driver mutation": true}, {"symptomatic, untreated brain metastases": true}, {"allogeneic organ transplant or prior cell therapy within the past 20 years": true}, {"any form of primary immunodeficiency": true}, {"on systemic steroid therapy \u2265 10 mg/day of prednisone or equivalent": true}, {"received a live or attenuated vaccination within 28 days prior to the start of treatment": true}, {"had another primary malignancy within the previous 3 years": true}, {"participation in another interventional clinical study within 21 days": true}]}}], "nctId": "NCT04614103", "title": "A Phase 2 Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (TIL or LN-145) in Patients With Metastatic Non-Small-Cell Lung Cancer"}